SECOND MODIFICATION TO COMMERCIAL PROMISSORY NOTECommercial Promissory Note • March 12th, 2004 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
THIS SECOND MODIFICATION TO COMMERCIAL PROMISSORY NOTE (“Modification”) is made and entered into as of this 31st day of December, 2003 by and between SALIX PHARMACEUTICALS, LTD., a Delaware corporation and SALIX PHARMACEUTICALS, INC., a California corporation (collectively, jointly and severally, “Borrower”) and RBC CENTURA BANK (“Bank”).
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. DATED 24th OF NOVEMBER 2003 DR. FALK PHARMA GmbH - and - SALIX PHARMACEUTICALS, INC. AMENDMENT AGREEMENTAmendment Agreement • March 12th, 2004 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
Portion of this exhibit marked [*] are omitted and are requested to be treated confidentially. LICENSE AGREEMENTLicense Agreement • March 12th, 2004 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • North Carolina
THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into effective this day of October 2003 (the “Effective Date”) between aaiPharma LLC, a Delaware limited liability company having an address at 2320 Scientific Park Drive, Wilmington, NC 28405, aaiPharma Inc., a Delaware corporation having an address at 2320 Scientific Park Drive, Wilmington, NC 28405 (hereinafter referred to collectively with aaiPharma LLC as “aaiPharma”), and Salix Pharmaceuticals, Inc., a California corporation having an address at 8540 Colonnade Center Drive, Suite 501, Raleigh, NC 27615 (hereinafter referred to as “Salix”).
